Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2014-01-28 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It is a regulatory filing used to report material information between annual reports (20-F or 40-F). The content describes a legal request related to warrant exercise period extension, which is a specific event update rather than a full financial report or earnings release. The document length is short (2012 characters), and it does not contain financial statements or detailed analysis. It is not an announcement of a report publication but a standalone regulatory update. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2014-01-28 English
FORM F-3
Capital/Financing Update Classification · 95% confidence The document is a Form F-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by RedHill Biopharma Ltd. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities to be registered, offering amounts, and legal disclaimers typical of a registration prospectus. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2014-01-23 English
FORM 6-K FILING DOCUMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release titled 'RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement.' The content focuses on a financing event (private placement) and does not contain detailed financial statements or comprehensive financial performance data. The document length is short (2158 characters), and it primarily announces a capital raising event. According to the definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, the document is best classified as a Capital/Financing Update (CAP).
2014-01-22 English
Regulatory Filings 2014
Regulatory Filings
2014-01-15 English
FORM 6-K FILING DOCUMENT
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. The content describes a private placement financing transaction, including details about the sale of shares and warrants, investors involved, use of proceeds, and terms of the warrants. This is an update on the company's capital raising activities rather than a full financial report or earnings release. The document is about a financing event and capital structure change, which fits the Capital/Financing Update category. The document length is 5431 characters, which is sufficient to contain substantive information about the financing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-01-14 English
FORM 6-K
Investor Presentation Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It references an upcoming presentation at healthcare conferences and provides a link to the presentation on the company's website. The document is short (2047 characters) and does not contain financial statements or detailed financial data. It primarily announces the availability of an investor presentation rather than containing the presentation itself. According to the 'Menu vs Meal' rule, such a document is best classified as an Investor Presentation (IP) since it is about a presentation made to investors and financial sector individuals, and the text indicates the presentation is available online. The document is not a report publication announcement because it includes some substantive information about the event and presentation, not just a notice of report availability. Therefore, the classification is Investor Presentation (IP) with high confidence.
2014-01-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.